Byondis, a new globally active pharmaceutical company focuses on intractable cancers and autoimmune diseases.
Based on proprietary technology, Byondis will create new precision drugs with a broad development pipeline, including anti-HER2 ADC [vic-] trastuzumab duocarmazine (SYD985) for breast cancer.
Byondis is a spin-off from Synthon Pharmaceuticals, a multinational that focuses mainly on high-quality generic and hybrid medicines.
Globrands' Pharmanaming and design agency VBAT developed the brand name and verbal and visual identity by interweaving their processes. Globrands responsible for positioning and brand story, brand essence, brand name and tagline, while VBAT was responsible for the logo and visual identity.
Byondis has a broad development pipeline, including advanced clinical programs, such as anti-Her2 ADC [vic-]trastuzumab duocarmazine (SYD985) for breast cancer. In the second half of 2020, Byondis is expecting results from its pivotal Tulip Phase III trial comparing SYD985 to the physician's choice treatment in patients with Her2-positive unresectable locally advanced or metastatic breast cancer. Submission of a Biological License Application is scheduled before the end of 2020.
Byondis anticipates entering the clinic with four additional programs in the course of 2020/2021. After progressing to clinical proof of concept, Byondis intends to enter into partnerships for late-stage development and commercialization.
Genuone is the leading pharmaceutical Contract Development Manufacturing Organization (CDMO) in South Korea, capable of providing wide coverage of drug dosage forms including oral solid, capsules, liquids, injections, and ointments.
Offering an extensive portfolio of pharmaceutical products essential to the future health and happiness of humanity, Genuone Sciences is launching a new era in the pharmaceutical and healthcare industry.
The name GENUONE was created to evoke the ideas of “GENUINE” and “ONE.” GEN, short for “genuine,” to convey the company's commitment to sincerity and loyalty toward customers. ONE signifies the determination to be The Best Team. Those values are fully instilled in the Genuone Sciences name. Recently established after the acquisition of well-known pharma businesses, Genuone Sciences is a specialized CMO pharmaceutical company that harnesses rich experience and advanced technology in drug development, clinical development capabilities and the most high-end production facilities in the nation. Genuone works to be trusted as a true partner for clients.
Indivion pharmacy dispenser
The INDIVION is the most cost-effective solution available on the market due to the reduction in manual labour and a minimal number of errors that equates to almost zero. This technology, together with the use of validated and certified materials, reduces the business risks for medicine dispensers but, more importantly, reduces health risks to patients. And, ultimately, that’s what it’s all about.
The fully-automated INDIVION medicine dosage system comprises an industrial robot that puts canisters, each filled with a specific medication, onto the correct docking stations so that the medications can be dispensed.
The INDIVION canisters each have a unique RFID tag from which the correct information can be read by a reader linked to the PHARYS database so that the reader can determine precisely which medications are in the machine, and how to control this specific canister for the correct dispensation of medicines. Single dose, multi dose, rush orders, expiry date-related changes, production related to method of treatment; all this is possible using the PHARYS software that helps safeguard the entire process-management chain in the central filling pharmacy together with the control of the INDIVION. The INDIVION has unrivalled capacity and produces up to 10,000 individual units per hour, while providing an absolute minimum risk of cross-contamination and incorrect dosage. The dispensation accuracy of 99.97% is also unrivalled in the market.
Want to learn more about the Indivion naming case? Contact us for a coffee and your questions
Esteya electronic brachytherapy
Nucletron, an Elekta company, and the world leader in brachytherapy, has launched Esteya®, the non-invasive solution for treating patients with skin cancer.
As treatment times are only two to three
minutes per visit, Esteya can be a great option
for patients with an active lifestyle.
Esteya provides a targeted yet gentle skin cancer treatment through the delivery of a precise high dose of radiation to the cancerous site,
minimizing radiation to surrounding healthy tissue, reducing the chance of scarring. Because the treatment is short and gentle, patients can expect a rapid recovery period and may return to their normal routine quickly.
Esteya is especially beneficial in treating cosmetically challenging areas such as the nose, lips, cheeks, temples and fingers, and for areas prone to wound closure problems, such as the shin and scalp. Esteya may also be the preferred option for patients for whom surgery presents a high intra-operative or post-operative risk of complications.
Esteya provides an elegant approach for treating skin cancer, featuring the right size and portability to be used anywhere in the clinic.
Want to learn more about the Esteya naming case? Contact us for a coffee and your questions
Covid-19 vaccine Skycovion
TSK bioscience’s Skycovion is Korea’s first domestically developed Covid-19 vaccine, listed for emergency use by the World Health Organization (WHO).
Skycovion is a recombinant vaccine that uses protein antigens. Inside the body, the antigens stimulate an immune response that creates antibodies to fight off the virus in case of infection.
Skycovion has small particles known as nano-particles containing parts of the spike protein found on the surface of SARS-CoV-2.
The vaccines will be especially helpful for people in developing countries as they can be stored in normal refrigerators at 2 to 8 degrees Celsius unlike Moderna and Pfizer vaccines, which use mRNA (messenger ribonucleic acid) technology and require extremely low temperatures to remain effective. SKYCovione received approval from a British regulator in May, becoming the first homegrown vaccine to gain sales approval in a foreign country.
“Based on the immunogenicity and safety profile, SKYCovione has become the first Korean vaccine to be put on the WHO EUL," said Ahn Jae-yong, SK bioscience CEO. "We will be committed to developing more vaccines to not just strengthen Korea's vaccine sovereignty, but also to enable equitable access of the vaccine.”
Want to learn more about the Skycovion naming case? Contact us for a coffee and your questions
Skycovion received approval from a British regulator in May 2023, becoming the first homegrown vaccine to gain sales approval in a foreign country.
Co-developed with the University of Washington’s Institute for Protein Design and funded by the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations, Skycovion is a recombinant vaccine that uses protein antigens. Inside the body, the antigens stimulate an immune response that creates antibodies to fight off the virus in case of infection. Skycovion has small particles known as nanoparticles containing parts of the spike protein found on the surface of SARS-CoV-2.